360 related articles for article (PubMed ID: 28456682)
1. Polygenic risk score predicts prevalence of cardiovascular disease in patients with familial hypercholesterolemia.
Paquette M; Chong M; Thériault S; Dufour R; Paré G; Baass A
J Clin Lipidol; 2017; 11(3):725-732.e5. PubMed ID: 28456682
[TBL] [Abstract][Full Text] [Related]
2. Risk of Premature Atherosclerotic Disease in Patients With Monogenic Versus Polygenic Familial Hypercholesterolemia.
Trinder M; Li X; DeCastro ML; Cermakova L; Sadananda S; Jackson LM; Azizi H; Mancini GBJ; Francis GA; Frohlich J; Brunham LR
J Am Coll Cardiol; 2019 Jul; 74(4):512-522. PubMed ID: 31345425
[TBL] [Abstract][Full Text] [Related]
3. Cardiovascular disease in familial hypercholesterolemia: Validation and refinement of the Montreal-FH-SCORE.
Paquette M; Brisson D; Dufour R; Khoury É; Gaudet D; Baass A
J Clin Lipidol; 2017; 11(5):1161-1167.e3. PubMed ID: 28801029
[TBL] [Abstract][Full Text] [Related]
4. The Montreal-FH-SCORE: A new score to predict cardiovascular events in familial hypercholesterolemia.
Paquette M; Dufour R; Baass A
J Clin Lipidol; 2017; 11(1):80-86. PubMed ID: 28391914
[TBL] [Abstract][Full Text] [Related]
5. Greater preclinical atherosclerosis in treated monogenic familial hypercholesterolemia vs. polygenic hypercholesterolemia.
Sharifi M; Higginson E; Bos S; Gallivan A; Harvey D; Li KW; Abeysekera A; Haddon A; Ashby H; Shipman KE; Cooper JA; Futema M; Roeters van Lennep JE; Sijbrands EJG; Labib M; Nair D; Humphries SE
Atherosclerosis; 2017 Aug; 263():405-411. PubMed ID: 28549500
[TBL] [Abstract][Full Text] [Related]
6. PCSK9 R46L, lower LDL, and cardiovascular disease risk in familial hypercholesterolemia: a cross-sectional cohort study.
Saavedra YG; Dufour R; Davignon J; Baass A
Arterioscler Thromb Vasc Biol; 2014 Dec; 34(12):2700-5. PubMed ID: 25278291
[TBL] [Abstract][Full Text] [Related]
7. Clinical Implications of Monogenic Versus Polygenic Hypercholesterolemia: Long-Term Response to Treatment, Coronary Atherosclerosis Burden, and Cardiovascular Events.
D'Erasmo L; Minicocci I; Di Costanzo A; Pigna G; Commodari D; Ceci F; Montali A; Brancato F; Stanca I; Nicolucci A; Ascione A; Galea N; Carbone I; Francone M; Maranghi M; Arca M
J Am Heart Assoc; 2021 May; 10(9):e018932. PubMed ID: 33890476
[TBL] [Abstract][Full Text] [Related]
8. Oligogenic familial hypercholesterolemia, LDL cholesterol, and coronary artery disease.
Tada H; Kawashiri MA; Nomura A; Teramoto R; Hosomichi K; Nohara A; Inazu A; Mabuchi H; Tajima A; Yamagishi M
J Clin Lipidol; 2018; 12(6):1436-1444. PubMed ID: 30241732
[TBL] [Abstract][Full Text] [Related]
9. ABO blood group is a cardiovascular risk factor in patients with familial hypercholesterolemia.
Paquette M; Dufour R; Baass A
J Clin Lipidol; 2018; 12(2):383-389.e1. PubMed ID: 29290540
[TBL] [Abstract][Full Text] [Related]
10. Detecting familial hypercholesterolemia by serum lipid profile screening in a hospital setting: Clinical, genetic and atherosclerotic burden profile.
Scicali R; Di Pino A; Platania R; Purrazzo G; Ferrara V; Giannone A; Urbano F; Filippello A; Rapisarda V; Farruggia E; Piro S; Rabuazzo AM; Purrello F
Nutr Metab Cardiovasc Dis; 2018 Jan; 28(1):35-43. PubMed ID: 28958694
[TBL] [Abstract][Full Text] [Related]
11. Elevated lipoprotein(a), hypertension and renal insufficiency as predictors of coronary artery disease in patients with genetically confirmed heterozygous familial hypercholesterolemia.
Chan DC; Pang J; Hooper AJ; Burnett JR; Bell DA; Bates TR; van Bockxmeer FM; Watts GF
Int J Cardiol; 2015 Dec; 201():633-8. PubMed ID: 26340131
[TBL] [Abstract][Full Text] [Related]
12. Family history and cardiovascular risk in familial hypercholesterolemia: data in more than 1000 children.
Wiegman A; Rodenburg J; de Jongh S; Defesche JC; Bakker HD; Kastelein JJ; Sijbrands EJ
Circulation; 2003 Mar; 107(11):1473-8. PubMed ID: 12654602
[TBL] [Abstract][Full Text] [Related]
13. Severe heterozygous familial hypercholesterolemia and risk for cardiovascular disease: a study of a cohort of 14,000 mutation carriers.
Besseling J; Kindt I; Hof M; Kastelein JJ; Hutten BA; Hovingh GK
Atherosclerosis; 2014 Mar; 233(1):219-23. PubMed ID: 24529147
[TBL] [Abstract][Full Text] [Related]
14. Polygenic contribution for familial hypercholesterolemia (FH).
Medeiros AM; Bourbon M
Curr Opin Lipidol; 2021 Dec; 32(6):392-395. PubMed ID: 34751168
[TBL] [Abstract][Full Text] [Related]
15. The molecular genetic basis and diagnosis of familial hypercholesterolemia in Denmark.
Jensen HK
Dan Med Bull; 2002 Nov; 49(4):318-45. PubMed ID: 12553167
[TBL] [Abstract][Full Text] [Related]
16. Cardiovascular risk factor profiles in familial hypercholesterolemia patients with and without genetic mutation compared to a nationally representative sample of adults in a high-risk European country.
Chlebus K; Zdrojewski T; Gruchała M; Gałąska R; Pajkowski M; Kocejko MR; Chmara M; Pencina MJ
Am Heart J; 2019 Dec; 218():32-45. PubMed ID: 31706143
[TBL] [Abstract][Full Text] [Related]
17. Diabetes is associated with an increased risk of cardiovascular disease in patients with familial hypercholesterolemia.
Paquette M; Bernard S; Ruel I; Blank DW; Genest J; Baass A
J Clin Lipidol; 2019; 13(1):123-128. PubMed ID: 30318454
[TBL] [Abstract][Full Text] [Related]
18. Polygenic Contribution to Low-Density Lipoprotein Cholesterol Levels and Cardiovascular Risk in Monogenic Familial Hypercholesterolemia.
Trinder M; Paquette M; Cermakova L; Ban MR; Hegele RA; Baass A; Brunham LR
Circ Genom Precis Med; 2020 Oct; 13(5):515-523. PubMed ID: 33079599
[TBL] [Abstract][Full Text] [Related]
19. Treatment Gaps in Adults With Heterozygous Familial Hypercholesterolemia in the United States: Data From the CASCADE-FH Registry.
deGoma EM; Ahmad ZS; O'Brien EC; Kindt I; Shrader P; Newman CB; Pokharel Y; Baum SJ; Hemphill LC; Hudgins LC; Ahmed CD; Gidding SS; Duffy D; Neal W; Wilemon K; Roe MT; Rader DJ; Ballantyne CM; Linton MF; Duell PB; Shapiro MD; Moriarty PM; Knowles JW
Circ Cardiovasc Genet; 2016 Jun; 9(3):240-9. PubMed ID: 27013694
[TBL] [Abstract][Full Text] [Related]
20. Familial hypercholesterolemia screening program in Bosnia and Herzegovina and cardiovascular morbidity.
Pojskic L; Pojskic B
Atherosclerosis; 2018 Oct; 277():278-281. PubMed ID: 30270059
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
